Jewish patients (Chappuis et al, 2000; Foulkes et al, 2000; Robson et al, 1998; Robson et al, 1999; Robson et al, 2004) .
A more precise estimate of CBC risk for a BRCA1/2-associated breast cancer patient is eagerly warranted, enabling more individualized counseling regarding surveillance versus prophylactic mastectomy, as well as selection of an optimal surveillance regimen for different mutation carrier groups. Age at diagnosis of the first breast cancer might be a potential risk stratifier. (Graeser et al, 2009; Metcalfe et al, 2004; Pierce et al, 2010; Rhiem et al, 2012; Robson et al, 2005; Verhoog et al, 2000) In this study we aim to give unbiased risk estimates of CBC risk by age at diagnosis of the first breast cancer for BRCA1 or BRCA2 mutation carriers compared to non-carriers diagnosed under age 50 in an unselected cohort, and explore the impact of other risk predicting factors. Additionally, we compared our results with previously published CBC risk estimates.
MeTHoDs

Patients
This retrospectively ascertained cohort study comprises a consecutive series of 7,403 female patients with invasive breast cancer diagnosed under the age of 50 years without a previous cancer diagnosis (except for non-melanoma skin tumors). Patients included in the study were treated for a first primary breast cancer between 1970 and 2003 in hospitals/centers throughout The Netherlands (Supplementary table 1 
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BRCA1/2 mutation carriership and contralateral breast cancer risk For 6,484 breast cancer patients (88% of total cohort) we were able to collect germline DNA of sufficient quality. Patients without germline DNA were from earlier years of breast cancer diagnosis, but had an age distribution similar to patients with germline DNA of sufficient quality. For 88% of these patients paraffin-embedded tissue blocks containing normal tissue were used for DNA isolation; for 12% DNA was obtained from blood.
The methods for DNA isolation and mutation analyses have been described elsewhere. (Schmidt & al, 2014) In short, BRCA1/2 mutation analysis included testing for 92 variants representing approximately 64% of the BRCA1/2 mutations prevalent in families in the Netherlands using Allelic discrimination or Fragment length analyses; Sanger sequencing was used for confirmation of mutations. (Schmidt & al, 2014) One patient identified with both a BRCA1 and BRCA2 mutation was classified as BRCA1 mutation carrier.
Using a coding procedure, the clinical data and BRCA1/2 mutation study results were anonymized before linkage. (Schmidt et al, 2009) The secondary use of long-term stored tissue samples and clinical data in this study was in accordance with the Dutch codes of conduct (http://www.federa.org/codes-conduct) (Riegman & van Veen, 2011) and approved by the review boards of the participating institutions.
For the analyses of CBC risks 190 patients were excluded: 52 patients with a synchronous bilateral breast cancer, 138 patients diagnosed with metastases or patients died or were lost to follow-up, within three months after the first breast cancer diagnosis; including 6,294 unilateral breast cancer patients in the analysis.
Statistical analysis
The main outcome of interest in our study was the risk for CBC, defined as a second primary invasive breast cancer in the contralateral breast in the original pathology and clinical records, and diagnosed at least three months after the diagnosis of the first breast cancer. Time at risk started three months after the diagnosis of the first breast cancer and ended at the date of diagnosis of CBC, contralateral mastectomy, first distant metastases, death or date of most recent follow-up information, whichever came first.
An oophorectomy, a new primary ipsilateral breast cancer or ovarian cancer, local recurrences, and regional recurrences were taken into account as time-varying covariates in the multivariate analyses. We report Standardized incidence ratios (SIRs) comparing the CBC incidence in our study population with the incidence of breast cancer in the Dutch female population (reference rates from the Netherlands Cancer Registry(van der Sanden et al, 1995) ) for BRCA1, BRCA2 mutation carriers and non-carriers separately, and stratified by follow-up period and age at diagnosis of the first breast cancer; see Supplementary information 1.
Absolute overall and subgroup risk estimates for BRCA1/2 mutation carriers and non-carriers were derived using cumulative incidence curves accounting for competing risks. First distant metastasis and death were taken into account as competing events.
The Fine and Gray method (Fine & Gray, 1999) was used for univariate and multivariate competing risk regression analyses to determine the subdistribution hazard ratios (HRs): see Supplementary information 2. Our main study aim was to estimate CBC risks for breast cancer patients who had not yet chosen for risk-reducing surgery while taking into account possible co-morbidities and death; to substantiate why we used the above-mentioned methods, three alternative methods are shown in Supplementary information 2 and Supplementary table 2. All statistical tests were two-sided; P<.05 was considered significant. Analyses were performed using STATA11.0.
Systematic review
A systematic review was performed including 21 studies which reported 10-year CBC risk estimates in BRCA1/2 mutation carriers; details of the methods and results are shown in Supplementary information 3 and summarized in forest plots.
ResulTs
Clinico-pathological characteristics of the 6,294 included breast cancer patients are shown in Supplementary table 1. Of all patients, 4.3% were identified carrying a BRCA1 (N=200) and/or BRCA2 (N=71) mutation. Associations between the BRCA1 and BRCA2 mutation status and different clinico-pathological characteristics are shown in Table 1 .
CBC risk in comparison with the breast cancer incidence of the Dutch female population under age 50
After a median follow-up of 12.5 years, 578 CBCs were observed in our study population, resulting in a significantly increased SIR of 3.01 (95%CI,2.77-3.27) compared to breast cancer rates in the general Dutch female population. Results for different subgroups of the cohort compared to breast cancer rates in the general population are shown in Supplementary table 3 and 4, and described in Supplementary information 1. Both for BRCA1/2 mutation carriers and non-carriers SIRs were highest for younger patients and in the first 5-years of follow-up.
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CBC risk in subgroups of the cohort
The 10-year cumulative CBC risk was 5.1% (95%CI,4.5-5.7) for non-carriers, 21.1% (95%CI,15.4-27.4) for BRCA1 mutation carriers and 10.8% (95%CI,4.7-19.6) for BRCA2 mutation carriers ( Figure 1A ; Supplementary CBC risks for subgroups according to age at breast cancer diagnosis and presence of a family history of (breast) cancer, stratified by the BRCA mutation status, are shown in Table   2 and Supplementary table 6. The 10-year cumulative risk of CBC for BRCA1/2 mutation carriers diagnosed with a first breast cancer before age 41 was 23.9% (95%CI, compared to 12.6% (95%CI,7.4-19.3) for those aged 40-49 years at diagnosis (Figure 1B; HR=1.89; 95%CI,1.09-3.29; P=.02). This age effect was not seen in non-carriers ( Figure   1A ; HR=1.06; 95%CI,0.89-1.28; P=.50), and there was statistically significant effect modification comparing BRCA1/2 carriers to non-carriers (P interaction =.05; Table 2 ). Including age as a linear factor showed similar results (per year increase: HR=1.00; 95%CI,0.98-1.01; P=.54 and HR=0.97; 95%CI,0.93-1.01; P=.10 for non-carriers and BRCA1/2 respectively; P interaction =.20). Including time-dependent interactions with oophorectomy, other second primaries of breast (ipsilateral) or ovaries, local recurrence, regional recurrence, and adjustment for treatment given for the first breast cancer did not substantially alter the results (Supplementary table 6 ). Also adjustment for the estrogen receptor status of the first breast cancer did not alter the results (data not shown). Analyses in BRCA1 mutation carriers alone also showed the effect of age, though not statistically significant (P interaction =.14; age diagnosis <41 vs. age diagnosis 41-49 years: HR BRCA1 =1.77; 95%CI,0.93-3.38; P=.08; Supplementary figure 1; Supplementary table 7). For BRCA1 and BRCA2 mutation carriers separately the 10-year cumulative CBC risks for those diagnosed before age 41 were 25.5% (95%CI,17.4-34.4) and 17.2% (95%CI,5.4-34.7) respectively, for those aged 41-49 years 15.6% (95%CI,8.5-24.5) and 7.2% (95%CI,1.9-17.5).
Adjuvant systemic therapy (any type) given for the first breast cancer decreased the risk for CBC in non-carriers. In BRCA1/2 mutation carriers there was also a suggestion for a decreased risk but the effect was not statistically significant ( *39 patients (29 non-carriers; 10 BRCA1 mutation carriers) were left censored as they had a contralateral mastectomy before or within three months after the first breast cancer diagnosis; †1049 patients were excluded because of missing systemic therapy data, 39 patients (29 non-carriers; 10 BRCA1 mutation carriers) were left censored as they had a contralateral mastectomy before or within three months after the first breast cancer diagnosis; ‡3709 patients were excluded because of missing family history data, 27 patients (20 non-carriers; 7 BRCA1 mutation carriers) were left censored as they had a contralateral mastectomy before or within three months after the first breast cancer diagnosis; ( Brekelmans et al, 2007; Eccles et al, 2001; Evans et al, 2013; Evans et al, 2010; GarciaEtienne et al, 2009; Graeser et al, 2009; Haffty et al, 2002; Hamann & Sinn, 2000; Kirova et al, 2010; Pierce et al, 2000; Rhiem et al, 2012; Robson et al, 2005; Robson et al, 2004; van der Kolk et al, 2010; Vencken et al, 2013; Verhoog et al, 1999; Verhoog et al, 2000) In Figure 2A the results of these studies are summarized in three forest plots; the range of reported 10-year CBC risks is 16.6-40% for BRCA1/2, 20.4-42%
for BRCA1, and 10.1-30% for BRCA2 mutation carriers, with our results at the lower end of the ranges. Five previous studies (Graeser et al, 2009; Rhiem et al, 2012; Verhoog et al, 2000) reported 10-year CBC risks for subgroups based on age at first breast cancer diagnosis ( Figure 2B ). For BRCA1/2 mutation carriers combined, the range of 10-year cumulative CBC risks reported was 23.7-30.7% (BRCA1:24-32%; BRCA2:17-29%) for mutation carriers diagnosed with a first breast cancer before age 40, and 8.4%-21% (BRCA1:11-52%; BRCA2:7-18%) for those after age 40. Again, our risk estimates are at the lower end of the range of previously published risk estimates.
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DIscussIon
In our unselected breast cancer patient cohort, we found 10-year cumulative CBC risks of 21.1% for BRCA1 mutation carriers and 10.8% for BRCA2 mutation carriers, which was 2-3 times higher than for non-carriers (HR=3.31 for BRCA1 and HR=2.17 for BRCA2 mutation carriers).
Aiming at an optimized and individualized counselling of BRCA1/2-associated breast cancer patients, it is important to identify factors which better predict the risk of CBC in for BRCA1/2 mutation carriers affected with a first breast cancer between 40-49 years (BRCA1:16%; BRCA2:7%). Age at first breast cancer diagnosis was also a predictor of CBC risk in the group of BRCA1 mutation carriers alone (although not significantly; probably because of the small numbers). Unfortunately, we could not draw firm conclusions about the effect of age in BRCA2 mutation carriers because the number of BRCA2 mutation carriers in our cohort was too small. On the other hand, the data of our study suggest that BRCA1 and BRCA2 are different entities also regarding the CBC risk (different SIRs for the time periods and higher cumulative CBC risk for BRCA1 over BRCA2).
Adjustment for treatment given for the first breast cancer and other events during follow-up (e.g. loco-regional recurrences) did not alter these results, indicating that these effects cannot be explained by a differential treatment effect in younger and older patients. As shown before, (Metcalfe et al, 2004; Reding et al, 2010) adjuvant systemic therapy decreased CBC risk in non-carriers in our study. A decreased risk was also seen in mutation carriers, though the effect was not statistically significant possibly due to small numbers. However, only few patients received hormonal treatment:
in the time period of this study, only post-menopausal women with estrogen receptor positive disease were considered for adjuvant hormonal therapy in The Netherlands (according to national guidelines www.CBO.nl/www.oncoline.nl (Rutgers et al, 2002) ).
Therefore, we were unable to study the effect of hormonal therapy separately.
We observed that family history is a predictor of CBC risk in both non-carriers and mutation carriers, which is in line with previous literature. Because of missing data regarding systemic therapy and family history in a large proportion of women (Supplementary table 1) , the numbers in these sub-analyses are small. Furthermore, the family history data we used were gathered from the clinical charts, and might therefore be of lesser quality; even though previously we showed sufficient correlation with data from the Clinical Genetic Center. (van den Broek et al, 2014) Therefore, results of family history sub-analyses should be interpreted with caution.
To our knowledge, the current cohort study is the first large study unselected for family history, which reports unbiased CBC risk estimates for BRCA1 and BRCA2 mutation carriers separately in comparison to non-carriers. Although the cohort in the current study is large, still a relatively small number of BRCA1/2 mutation carriers were included, especially accounting for BRCA2 mutation carriers. Since we were unable to test for all known BRCA1/2 mutations, some BRCA1/2 mutation carriers may have been misclassified as non-carriers.
Assuming these rare mutations are of equal penetrance, this may have led to a slight underestimation of the CBC risks. (Schmidt & al, 2014) In the analyses we corrected for prophylactic measures, though the effect on CBC prevention (Domchek et al, 2010; Rebbeck et al, 2009) was not an endpoint in the current paper. Importantly, as a large part of patients was diagnosed before 1995, many BRCA1/2 mutation carriers were unaware of their mutation status at diagnosis. (Schmidt et al, 2009; van den Broek et al, 2014) The 10-year CBC risk estimates for BRCA1/2 mutation carriers found in the present study are of the same magnitude as published previously; i.e.,13-42 percent, with BRCA2 mutation carriers tending to be in the lower part of this range. (Brekelmans et al, 2007; Eccles et al, 2001; Evans et al, 2013; Evans et al, 2010; Garcia-Etienne et al, 2009; Graeser et al, 2009; Haffty et al, 2002; Hamann & Sinn, 2000; Kirova et al, 2010; Pierce et al, 2000; Rhiem et al, 2012; Robson et al, 2005; Robson et al, 2004; van der Kolk et al, 2010; Vencken et al, 2013; Verhoog et al, 1999; Verhoog et al, 2000) The variation in all reported risk estimates is large, which reflects on one hand the heterogeneity of breast cancer in the different groups (and thus the differential effect of various factors, such as treatment), and on the other hand methodological aspects. There is no consensus about a precise CBC risk estimate that can be communicated to physicians and their patients. Almost all published studies suffered from potential selection and testing bias, including 'selected' high risk BRCA1/2 mutation carriers, e.g. from CGCs, and might therefore have overestimated the risk of CBC. Furthermore, only three studies accounted for competing risks in their analyses, which is important to prevent risk overestimation. (Gooley et al, 1999) In our own study with unselected mutation carriers and accounting for competing risks we found a 10-year CBC risk for BRCA1/2 mutation carriers of 18%. Four studies including 'selected' patients and accounting for competing risks
6
BRCA1/2 mutation carriership and contralateral breast cancer risk reported higher risk estimates ranging between 21-27% (Garcia-Etienne et al, 2009; Robson et al, 2004; Vencken et al, 2013) , which was similar to the 10-year CBC risk observed in our study for mutation carriers with a family history of breast cancer (25%; Table 2 ). In conclusion, the overall 10-year CBC risk for unselected BRCA1/2 mutation carriers will be around 18%, while for "selected" mutation carriers the risk will be somewhat higher around 21-27%; with BRCA2 mutation carriers being at the lower and BRCA1 mutation carriers at the higher end of this range (Figure 3) . Furthermore, based on our study and those published previously, age at primary breast cancer diagnosis is an important predictor of the CBC risk in BRCA1/2 mutation carriers, with a range of 10-year cumulative CBC risks of 23.7%-30.7% for mutation carriers diagnosed with the first breast cancer before age 40 (BRCA1:24-32%; BRCA2:17-29%), and 8.4%-21% for those diagnosed aged after age 40 (BRCA1:11-52%; BRCA2:7-18%) ( Figure 3 ).In our study we found the highest CBC risk in BRCA1/2 mutation carriers diagnosed at young ages who also had a family history of breast cancer (10-year cumulative CBC risk of 38.1% (95%CI,23.5-52.6)). This is in concordance with previously published risk estimates, which were mainly based on BRCA1/2 carriers recruited through clinical genetic centers, i.e. those with a substantial family history.
In view of the fact that genetic testing is increasingly done, it is important to be able to provide precise and unbiased risk estimates of contralateral breast cancer for a BRCA1/2-associated breast cancer patient. The data of the current study contribute to further knowledge on CBC risks for this group of high risk woman enabling to improve counseling regarding the optimal strategy concerning prophylactic mastectomy versus surveillance, as well as optimal screening regimens in the follow-up after breast cancer. Our reported agespecific risks, as shown in Figure 3 , can be taken into account when counseling BRCA1/2 mutation carriers regarding prophylactic mastectomy versus optimal screening.
figure 3: Summary of the 10-year cumulative CBC risks for non-carriers and BRCA1/2 mutation carriers, stratified on the risk predictor (age) of this study in patients under 50 years of age. We compared the CBC incidence in our study population with the incidence of breast cancer in the Dutch female population (reference rates from the Netherlands Cancer Registry(van der Sanden et al, 1995)) for BRCA1, BRCA2 mutation carriers and noncarriers separately, and stratified by follow-up period and age at diagnosis of the first breast cancer using Standardized incidence ratios (SIRs).
SIRs were determined as the ratio of the observed and expected numbers of CBCs in the study population taking into account person-years of observation in our cohort by age, calendar period and follow-up interval. Confidence limits of the SIRs were calculated using exact Poisson probabilities of observed numbers. (Breslow & Day, 1987) P-values for tests were calculated using Chi-square test statistics. Absolute Excess Risks (AERs)
were calculated by subtracting the expected number of CBCs from the observed number, dividing by person-years at risk and multiplied by 10,000.
After a median follow-up of 12.5 years, 578 CBCs were observed in our study population, resulting in a significantly increased SIR of 3.01 (95%CI, 2.77-3.27) compared to breast cancer rates in the general Dutch female population. For BRCA1 and BRCA2 mutation carriers the SIRs were 14.5 (95%CI, 10.6 to 19.4) and 7.9 (95%CI, 4.07-13.7) , respectively, while for non-carriers the SIR was 2.78 (95%CI, 2.55-3.27) (Supplementary table 3).
For both mutation carriers and non-carriers, SIRs were highest in the first 5 years of supplementary information 2: additional information on the statistical methods.
Statistical methods cumulative incidence curves accounting for competing risks
Absolute overall and subgroup risk estimates for BRCA1/2 mutation carriers and noncarriers were derived using cumulative incidence curves accounting for competing risks.
First distant metastasis and death were taken into account as competing events. The Fine
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BRCA1/2 mutation carriership and contralateral breast cancer risk and Gray method (Fine & Gray, 1999) was used for univariate and multivariate regression analyses to determine the subdistribution hazard ratios (HRs). Factors included in the multivariate analysis were age at first breast cancer diagnosis (continuous), time-interactions with oophorectomy, ipsilateral breast or ovarian cancer, local recurrences, and regional recurrences, adjuvant radiotherapy (no/yes/missing) and systemic treatment (none/chemotherapy/hormonal therapy/both/missing) given for the first breast cancer.
When assessing interaction, the coefficient of the interaction term was used to determine the subdistribution hazard ratio (HR) for CBC risk related to a specific factor in both non-carriers and BRCA1/2 mutation carriers. The proportional hazard assumption was verified comparing log-minus-log and hazard curves with each other. To handle missing values regarding systemic treatment and family history of breast cancer (Supplementary   table 1) , patients with missing data were excluded for the subset of subgroup-analyses including the variables concerned.
Three additional statistical methods for analyzing the CBC risk
We used In the method used for analyzing the data, as shown in the main text, time at risk started three months after the diagnosis of the first breast cancer and ended at the date of diagnosis of the CBC, contralateral breast mastectomy, first distant metastasis, death or date of most recent follow-up information, whichever came first. First distant metastasis and death were taken into account as competing events. We did not censor on oophorectomy, ipsilateral breast cancer or ovarian cancer, local recurrences, and regional recurrences, but these events were taken into account as time-varying covariates in the multivariate analyses.
Supplementary table 2-I shows the results of the data analyzed by the same method as used in the main text, except that time at risk in the estimation of the cumulative incidence curves was censored additionally for oophorectomy. Our aim was to determine CBC risks for patients who not yet underwent prophylactic surgery; therefore, stopping time at risk at oophorectomy seemed to be logical. However, in our cohort the reason for oophorectomy was largely unknown (n total = 525: 15% prophylactic; 7% 
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BRCA1/2 mutation carriership and contralateral breast cancer risk as treatment for breast cancer; 78% unknown). To suit our aim, stopping time at risk at oophorectomy would preferably only be done when it is performed for prophylactic reasons. Secondly, and most importantly, oophorectomy is shown to decrease the risk of breast cancer, (Bermejo-Perez et al, 2007; Narod, 2010; Rebbeck et al, 2009 ) though we did not observe this in our data (HR, 1.00; 95% CI, 0.68 to 1.45; P < .99) and a recent publication has challenged this view . . (Heemskerk-Gerritsen et al, 2015) This is probably due to indication bias: patients with the highest risk will more often opt for risk-reducing surgery. In our dataset, 108 patients had an oophorectomy before or at diagnosis and would not contribute to the time at risk when censoring on oophorectomy, while these were probably the patients with the highest CBC risk a priori (e.g. 8% of non-carriers vs.
16% of BRCA mutation carriers underwent an oophorectomy in our study taking contralateral mastectomy into account as a competing event. It is plausible that in our study many of the contralateral mastectomies were for prophylactic reasons (only partly known in our data: 35% prophylactic; 30% for a recurrence/non-invasive tumor;
35% unknown) and because the CBC risk after a mastectomy is very small (no influence of indication bias), censoring on contralateral mastectomy but not taking it into account as competing events suits our aim best.
Supplementary table 2-III shows the results of the data analyzed by the same method as used in the main text, except that distant metastasis and death were censored and not taken into account as competing events. Breast cancer patients are at risk of developing metastasis after their breast cancer diagnosis. Especially, BRCA1/2 mutation carriers may exhibit unfavorable prognostic factors, e.g. there is a higher frequency of triple negative tumors in BRCA1 mutation carriers. (Honrado et al, 2006; Phillips, 2001) When not taking into account metastasis and death as competing events, the CBC risk is estimated for patients for whom you assume none these events occur, and an overestimation of the absolute risk for CBC might occur. (Gooley et al, 1999) When comparing the cumulative risks of this analysis (Supplementary table 2-III) and the cumulative risks as described in the main text (Supplementary table 5) , the risks are much higher when not taking into account these competing events. Interestingly, most previously published studies did not take into account competing events in their analysis. Figure 2A and 2B show previously published 10-year CBC risks compared to our results with and without taking into account competing events. The risks reported by studies not taking into account competing events seem to be higher than the risk reported by the other studies.
supplementary information 3: Review of previously published risk estimates and comparison with current study results.
We performed a systematic review on studies that published absolute CBC risks for BRCA1/2 mutation carriers. We searched Pubmed until March 2014 using the term: Contralateral breast cancer AND BRCA* (no limits were set). This retrieved 188 titles of which we identified 21 published studies reporting 10-year cumulative CBC risk estimates for BRCA1 and/or BRCA2 mutation carriers. (Brekelmans et al, 2007; Eccles et al, 2001; Evans et al, 2013; Evans et al, 2010; Garcia-Etienne et al, 2009; Graeser et al, 2009; Haffty et al, 2002; Hamann & Sinn, 2000; Kirova et al, 2010; Pierce et al, 2000; Rhiem et al, 2012; Robson et al, 2005; Robson et al, 2004; van der Kolk et al, 2010; Vencken et al, 2013; Verhoog et al, 1999; Verhoog et al, 2000) We extracted the risk estimates from these observational studies and summarized these in forest plots. The forest plots also include the present study (Figure 2 ). Here the results are summarized and discussed in more detail.
In the large WECARE-study patients with a CBC were matched to patients with unilateral breast cancer and screened for BRCA1/2 mutations, using the case-control method to estimate the 10-year CBC risk for mutation carriers and non-carriers. All the other studies followed BRCA1/2 mutation carriers over time; most of these studies ascertained the BRCA1/2 mutation carriers through CGCs, and some studies included multiple carriers from one family. (Brekelmans et al, 2007; Eccles et al, 
BRCA1/2 mutation carriership and contralateral breast cancer risk 2001; Evans et al, 2013; Evans et al, 2010; Garcia-Etienne et al, 2009; Graeser et al, 2009; Haffty et al, 2002; Hamann & Sinn, 2000; Kirova et al, 2010; Pierce et al, 2000; Rhiem et al, 2012; Robson et al, 2005; Robson et al, 2004; van der Kolk et al, 2010; Vencken et al, 2013; Verhoog et al, 1999; Verhoog et al, 2000) In Figure 2A the results of these studies are summarized in three forest plots for the different mutation groups; we observed a large range of reported 10-year absolute CBC risks, for BRCA1/2 mutation carriers:16.6% -40%; for BRCA1 mutation carriers: 20.4% -42%: and for BRCA2 mutation carriers:
10.1% -30%.
There are several reasons which may explain this large range related to the design of the studies and the analyses in the papers reviewed. Selection or testing bias may have occurred in the studies including BRCA1/2 mutation carriers from CGCs (with an obvious family history or very young age at breast cancer diagnosis) compared to studies including BRCA1/2 mutation carriers from breast cancer patient cohorts unselected for family history. The CGC studies possibly selected for mutation carriers with the most penetrant mutations as women with a strong family history of breast cancer are more likely to have been referred for genetic testing; and different mutations may lead to different risks for breast cancer. (2014) Additionally, as most of these studies included BRCA1/2 mutation carriers retrospectively, it is possible that the referral of the respective (index) patient to the CGC was based on the occurrence of a CBC; consequently, CBCs become overrepresented in this group and overestimation of the CBC risk can occur (ascertainment bias). Only two studies tested a consecutive series of breast cancer patients for BRCA1 and/or BRCA2 mutations; these studies were small (maximum 57 mutation carriers) and included enriched populations of young patients (under 42 years of age) (Haffty et al, 2002) and of Ashkenazi Jewish patients (Robson et al, 2004) . The 10-year CBC absolute risk estimates for BRCA1/2 mutation carriers from these studies were 28 and 27% respectively; in the middle of the range of risk estimates reported by studies using mutation carriers selected through CGCs (range reported: 16.6 -40%, Figure 2A ). The WECARE and our own study, including less selected breast cancer patients younger than 55 and 50 years at diagnosis, showed lower risk estimates of 18.3 and 18.4% respectively.
Another important factor possibly playing a role in the heterogeneity of the CBC risk estimates across studies is that competing events were not always are taken into account in the analyses. Breast cancer patients are at risk of developing metastases after breast cancer diagnosis depending on stage at diagnosis and treatment given; moreover, especially BRCA1/2 mutation carriers may exhibit unfavorable prognostic factors, e.g. a high frequency of triple negative tumors in BRCA1 mutation carriers. (Honrado et al, 2006; Phillips, 2001) When not taking into account metastases and death as competing risks, the CBC risk is estimated assuming none of these events occurred, which may lead to an overestimation of the absolute CBC risk. (Gooley et al, 1999) Of all studies reporting the 10-year cumulative CBC risk for BRCA1/2 mutations carriers, only three studies (GarciaEtienne et al, 2009; Robson et al, 2004) took into account competing events (mainly death; Figure 2A ), and indeed reported somewhat lower risk estimates.
Also, when performing the analyses in our own study without considering competing events (Supplementary table 2-III), our CBC risk estimates were higher compared to the estimates from analyses accounting for competing events and more in the middle of the range of previously published estimates (Figure 2A ). To our knowledge, there are no published studies that used competing risk analysis to assess CBC risks for BRCA1 and BRCA2 mutation carriers separately.
Five previous studies (Graeser et al, 2009; Rhiem et al, 2012; Verhoog et al, 2000) reported 10-year CBC risks for subgroups based on age at first breast cancer diagnosis; shown in the forest plots in Figure 2B . All studies showed an increased CBC risk for BRCA1 and/or BRCA2 mutation carriers diagnosed with breast cancer at a younger age (< ±40 years) compared to the mutation carriers diagnosed with breast cancer at an older age (>±40 years). The only outlier was reported by Verhoog and colleagues (Verhoog et al, 2000) , who found a high 10-year CBC risk of 52%
for BRCA1 mutation carriers diagnosed with breast cancer between 40 -49 years, but did not speculate on the reasons for their findings. In the studies reporting on BRCA1/2 mutation carriers combined, the range of 10-year cumulative CBC risks reported was 23.7% -30.7% for mutation carriers diagnosed with a first breast cancer before age 40, and was 8.4% -21% for mutation carriers affected with breast cancer after age 40. None of the published studies adjusted for competing events in the analyses. Furthermore, two studies included only BRCA1/2 mutation carriers identified through CGCs. In concordance, our risk estimates are at the lower end of the range of previously published risk estimates (Figure 3 ).
BRCA1/2 mutation carriership and contralateral breast cancer risk supplementary 39 patients (29 non-carriers; 10 BRCA1 mutation carriers) were left censored as they had a contralateral mastectomy before or within three months after the first breast cancer diagnosis; No. number of patients at the start of follow-up; No. CBCs number of CBCs during follow-up; 5-year 5-year cum CBC risk; 10-year 10-year cum CBC risk; 15-year 15-year cum CBC risk; HR a hazard ratio adjusted for age at diagnosis first breast cancer; HR b hazard ratio adjusted for age at diagnosis first breast cancer, time-interaction with oophorectomy, time interaction with ipsilateral breast cancer and second ovarian cancer, time interaction with local recurrences, and time interaction with regional recurrences; HR c hazard ratio adjusted for age at diagnosis first breast cancer, time-interaction with oophorectomy, time interaction with ipsilateral breast cancer and second ovarian cancer, time interaction with local recurrences, time interaction with regional recurrences, systemic therapy, and radiotherapy; 95% CI 95% confidence interval; P p-value from Wald test statistic.
iii: Cox regression analysis: censoring on metastasis, death and contralateral mastectomy; oophorectomy ignored in the cumulative CBC risk estimations and taken into account time-varying in the adjusted models.
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